Guillain-Barré Syndrome

Ximena Arcila-Londono; Richard A. Lewis

doi:10.1055/s-0032-1329196

Seminars in Neurology, Table of Contents

Semin Neurol 2012; 32(03): 179-186
DOI: 10.1055/s-0032-1329196

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Guillain-Barré Syndrome

Ximena Arcila-Londono

¹Henry Ford Health System Department of Neurology

,

Richard A. Lewis

²Department of Neurology, Wayne State University School of Medicine, Detroit, MI

› Author Affiliations

Abstract

Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy, which has various clinical presentations and both axonal and demyelinating forms. The original description of “ascending paralysis” encompasses the most common varieties: the primary demyelinating form, acute inflammatory demyelinating polyneuropathy (AIDP), and some of the axonal forms, acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN). However, there are now well-documented acute “monophasic” polyneuropathies that have a different clinical phenomenology than that described originally by Guillain, Barré, and Strohl: Miller Fisher syndrome, pure sensory neuropathy/neuronopathy, pandysautonomia, and oropharyngeal variant. Here the authors review both typical GBS (AIDP, AMAN, and AMSAN), and variant syndromes with a focus on clinical and diagnostic features, pathologic findings, pathogenesis, and treatment.

Keywords

Guillain-Barré syndrome - acute inflammatory demyelinating polyradiculoneuropathy - acute motor axonal neuropathy - acute motor and sensory axonal neuropathy - Fisher syndrome

Full Text

References

References
1 Haymaker WE, Kernohan JW. The Landry-Guillain-Barré syndrome; a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine (Baltimore) 1949; 28 (1) 59-141
2 Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255 (2) 57-65
3 Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366 (9497) 1653-1666
4 McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32 (2) 150-163
5 Rocha MS, Brucki SM, Carvalho AA, Lima UW. Epidemiologic features of Guillain-Barré syndrome in São Paulo, Brazil. Arq Neuropsiquiatr 2004; 62 (1) 33-37
6 van Koningsveld R, Rico R, Gerstenbluth I , et al. Gastroenteritis-associated Guillain-Barré syndrome on the Caribbean island Curaçao. Neurology 2001; 56 (11) 1467-1472
7 Hadden RDM, Cornblath DR, Hughes RAC , et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998; 44 (5) 780-788
8 McKhann GM, Cornblath DR, Ho TW , et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991; 338 (8767) 593-597
9 Kannan MA, Ch RK, Jabeen SA, Mridula KR, Rao P, Borgohain R. Clinical, electrophysiological subtypes and antiganglioside antibodies in childhood Guillain-Barré syndrome. Neurol India 2011; 59 (5) 727-732
10 Shafqat S, Khealani BA, Awan F, Abedin SE. Guillain-Barré syndrome in Pakistan: similarity of demyelinating and axonal variants. Eur J Neurol 2006; 13 (6) 662-665
11 Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986; 43 (11) 1150-1152
12 Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. Guillain-Barré syndrome variants in Emilia-Romagna, Italy, 1992-3: incidence, clinical features, and prognosis. J Neurol Neurosurg Psychiatry 1998; 65 (2) 218-224
13 Lyu RK, Tang LM, Cheng SY, Hsu WC, Chen ST. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 1997; 63 (4) 494-500
14 Yuan CL, Wang YJ, Tsai CP. Miller Fisher syndrome: a hospital-based retrospective study. Eur Neurol 2000; 44 (2) 79-85
15 McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009; 32 (2) 150-163
16 Hadden RDM, Karch H, Hartung H-P , et al; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001; 56 (6) 758-765
17 Lasky T, Terracciano GJ, Magder L , et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998; 339 (25) 1797-1802
18 Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009; 169 (3) 382-388
19 Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27 (Suppl) S21-S24
20 Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 1991; 41: 617-618
21 Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology 2005; 65 (1) 138-140
22 Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1985; 8 (6) 528-539
23 Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barré polyneuropathy. Brain 1984; 107 (Pt 1) 219-239
24 Brown WF, Snow R. Patterns and severity of conduction abnormalities in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1991; 54 (9) 768-774
25 Bromberg MB. Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy. Muscle Nerve 2011; 43 (6) 780-794
26 Prineas JW. Pathology of the Guillain-Barré syndrome. Ann Neurol 1981; 9 (Suppl) 6-19
27 Hafer-Macko CE, Sheikh KA, Li CY , et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996b; 39 (5) 625-635
28 Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review. J Neuroimmunol 2010; 223 (1-2) 5-12
29 Winer JB. Guillain-Barré syndrome: clinical variants and their pathogenesis. J Neuroimmunol 2011; 231 (1-2) 70-72
30 Hardy TA, Blum S, McCombe PA, Reddel SW. Guillain-barré syndrome: modern theories of etiology. Curr Allergy Asthma Rep 2011; 11 (3) 197-204
31 Hardy TA, Blum S, McCombe PA, Reddel SW. Guillain-Barré syndrome: modern theories of etiology. Curr Allergy Asthma Rep 2011; 11 (3) 197-204
32 Griffin JW, Li CY, Ho TW , et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996; 39 (1) 17-28
33 Feasby TE, Gilbert JJ, Brown WF , et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986; 109 (Pt 6) 1115-1126
34 Griffin JW, Li CY, Ho TW , et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996; 39 (1) 17-28
35 Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann Neurol 1995; 37 (4) 436-442
36 Fross RD, Daube JR, Fukutake T, Yuki N, Hattori T. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology 1987; 37 (9) 1493-1498
37 Fross RD, Daube JR. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology 1987; 37: 1493-1498
38 Ogawara K, Kuwabara S, Yuki N. Fisher syndrome or Bickerstaff brainstem encephalitis? Anti-GQ1b IgG antibody syndrome involving both the peripheral and central nervous systems. Muscle Nerve 2002; 26 (6) 845-849
39 Yuki N, Taki T, Takahashi M , et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994; 36 (5) 791-793
40 Chaudhry F, Gee KE, Vaphiades MS, Biller J, Jay W. GQ1b antibody testing in Guillain-Barre syndrome and variants. Semin Ophthalmol 2006; 21 (4) 223-227
41 Phillips MS, Stewart S, Anderson JR. Neuropathological findings in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 1984; 47 (5) 492-495
42 Barontini F, Di Lollo S, Maurri S, Lambruschini P. Localization of the pathological process in Miller Fisher syndrome. Ital J Neurol Sci 1992; 13 (3) 221-225
43 Buchwald B, Bufler J, Carpo M , et al. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 2001; 56 (1) 67-74
44 Bullens RW, Halstead SK, O'Hanlon GM , et al. Concanavalin A inhibits pathophysiological effects of anti-ganglioside GQ1b antibodies at the mouse neuromuscular synapse. Muscle Nerve 2005; 31 (6) 751-760
45 Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol 2007; 64 (10) 1519-1523
46 Kashihara K, Shiro Y, Koga M, Yuki N. IgG anti-GT1a antibodies which do not cross react with GQ1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1998; 65 (5) 799
47 Koga M, Yuki N, Ariga T, Morimatsu M, Hirata K. Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome?. J Neuroimmunol 1998; 86 (1) 74-79
48 Arai M, Susuki K, Koga M. Axonal pharyngeal-cervical-brachial variant of Guillain-Barré syndrome without Anti-GT1a IgG antibody. Muscle Nerve 2003; 28 (2) 246-250
49 Notturno F, Caporale CM, Uncini A. Acute sensory ataxic neuropathy with antibodies to GD1b and GQ1b gangliosides and prompt recovery. Muscle Nerve 2008; 37 (2) 265-268
50 Koike H, Atsuta N, Adachi H , et al. Clinicopathological features of acute autonomic and sensory neuropathy. Brain 2010; 133 (10) 2881-2896
51 Fagius J, Westerberg CE, Olsson Y. Acute pandysautonomia and severe sensory deficit with poor recovery. A clinical, neurophysiological and pathological case study. J Neurol Neurosurg Psychiatry 1983; 46 (8) 725-733
52 Struhal W, Hödl S, Mazhar S, Ransmayr G. Acute pandysautonomia—restitutio ad integrum by high prednisolone therapy. Wien Klin Wochenschr 2011; 123 (15-16) 508-511
53 Hughes RA, Wijdicks EF, Benson E , et al; Multidisciplinary Consensus Group. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005; 62 (8) 1194-1198
54 Walgaard C, Lingsma HF, Ruts L , et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 2010; 67 (6) 781-787
55 The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology 1985; 35 (8) 1096-1104
56 Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2002; 2 (2) CD001798
57 Walgaard C, Jacobs BC, van Doorn PA. Emerging drugs for Guillain-Barré syndrome. Expert Opin Emerg Drugs 2011; 16 (1) 105-120
58 van der Meché FG, Schmitz PI. Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326 (17) 1123-1129
59 Hughes RA, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2001; 2 (2) CD002063
60 Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002; 59 (12) (Suppl. 06) S13-S21
61 Kuitwaard K, de Gelder J, Tio-Gillen AP , et al. Pharmokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009; 66: 597-603
62 Kuitwaard K, de Gelder J, Tio-Gillen AP , et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009; 66 (5) 597-603
63 Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 1997; 350 (9093) 1747
64 van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007; 6 (7) 589-594
65 Halstead SK, Zitman FM, Humphreys PD , et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008; 131: 1197-1208
66 Pritchard J, Gray IA, Idrissova ZR , et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology 2003; 61 (9) 1282-1284
67 Garssen MP, van Koningsveld R, van Doorn PA , et al. Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry 2007; 78 (9) 1012-1013 . Erratum in: J Neurol Neurosurg Psychiatry 2007 Dec;78(12):1416
68 Bechtold DA, Yue X, Evans RM, Davies M, Gregson NA, Smith KJ. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 2005; 128 (Pt 1) 18-28
69 Bensa S, Hadden RD, Hahn A, Hughes RA, Willison HJ. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study. Eur J Neurol 2000; 7 (4) 423-426
70 Bever Jr CT, Young D, Anderson PA , et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994; 44 (6) 1054-1059
71 Kaida K, Ariga T, Yu RK. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders—a review. Glycobiology 2009; 19 (7) 676-692